ArticleJournal of the American Society of Nephrology : JASN2026
B -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05978661 (A Single-Center Exploratory Study to Evaluate the Safety and Efficacy of FKC288 in Subjects With Relapsed or Refractory Systemic Light Chain), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Center Exploratory Study to Evaluate the Safety and Efficacy of FKC288 in Subjects With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Who cites it
2 citing papers in PubMed.
- Selective Immune Reprogramming or Broad Immune Ablation with BCMA-CD19 Dual-Targeted CAR- T Cells in AL Amyloidosis.Journal of the American Society of Nephrology : JASN · 2026Article
- Dual B -Cell Maturation Antigen/CD19 Chimeric Antigen Receptor- T Therapy for AL Amyloidosis : Targeting the Clone, Saving the Kidney.Journal of the American Society of Nephrology : JASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
key pointsThis study evaluated the safety and efficacy of B -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor- T -cell therapy for patients with relapsed/refractory AL amyloidosis. B -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor- T -cell therapy was well tolerated and no dose limiting toxicity occurred. Single-cell analysis confirmed B -cell maturation antigen-CD19 chimeric antigen receptor- T -cell enabled complete elimination of pathogenic plasma and B cells and promoted immune reconstitution.
backgroundThe potential efficacy of chimeric antigen receptor (CAR)- T cells for the treatment of relapsed/refractory systemic light chain (AL) amyloidosis remains elusive. This study aimed to investigate the efficacy and safety of B -cell maturation antigen (BCMA)-CD19 dual-targeted CAR- T -cell therapy in patients with refractory/relapsed AL amyloidosis in a single-center exploratory trial.
methodsThe key eligibility criteria of this trial were patients with AL amyloidosis and at least one major organ involvement who were refractory to or had relapsed from at least two lines of therapy. The primary outcome was the safety of CAR- T therapy. All eligible patients received a single infusion of 0.3×10 6 /kg the BCMA-CD19 dual-targeted CAR- T cells after preconditioning with fludarabine (30 mg/m 2 per day for 3 days) and cyclophosphamide (300 mg/m 2 per day for 3 days).
resultsNotably, six patients with refractory/relapsed AL amyloidosis were enrolled, all of whom had kidney involvement, and one of whom had cardiac involvement with Mayo stage 3a disease. After a median follow-up of 640 (range, 563-745) days, all six patients achieved hematologic complete response (100%, 95% confidence interval, 54% to 100%) and renal response (100%, 95% confidence interval, 54% to 100%). The median time to hematologic response and renal response were 9 (interquartile range, 6-11) and 75 (interquartile range, 18-180) days, respectively. One patient relapsed at month 6, while the other patients remained in remission. Grade 1 cytokine release syndrome occurred in two patients, and no immune effector cell-associated neurotoxicity syndrome was identified. Pneumonia occurred in two of the six patients. One patient had grade 3 urticaria and grade 2 AKI. One patient developed acute promyelocytic leukemia 15 months post-CAR- T -cell therapy. Single-cell RNA/ B -cell receptor sequencing confirmed that BCMA-CD19 dual-targeted CAR- T cells enabled the comprehensive clearance of pathogenic plasma cells and aberrant B cells, while also promoting endogenous immune reconstitution in AL amyloidosis.
conclusionsThis study provides preliminary evidence for the feasibility and tolerability of BCMA-CD19 dual-targeting CAR- T -cell therapy, and it showed promising activity in patients with relapsed/refractory AL amyloidosis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT05978661 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.